Beović, Bojana; Doušak, May; Ferreira-Coimbra, João; Nadrah, Kristina; Rubulotta, Francesca; Belliato, Mirko; Berger-Estilita, Joana; Ayoade, Folusakin; Rello, Jordi; Erdem, Hakan (2020). Antibiotic use in patients with COVID-19: a 'snapshot' Infectious Diseases International Research Initiative (ID-IRI) survey. Journal of antimicrobial chemotherapy, 75(11), pp. 3386-3390. Oxford University Press 10.1093/jac/dkaa326
|
Text (Original article collaboration)
Antibiotic use in patients with COVID-19_Berger Estilita_J Antimicrobial Chemo_2020.pdf - Published Version Available under License Publisher holds Copyright. Author holds Copyright Download (718kB) | Preview |
BACKGROUND
Antibiotics may be indicated in patients with COVID-19 due to suspected or confirmed bacterial superinfection.
OBJECTIVES
To investigate antibiotic prescribing practices in patients with COVID-19.
METHODS
We performed an international web-based survey and investigated the pattern of antibiotic use as reported by physicians involved in treatment of COVID-19. SPSS Statistics version 25 was used for data analysis.
RESULTS
The survey was completed by 166 participants from 23 countries and 82 different hospitals. Local guidelines for antibiotic use in COVID-19 patients were reported by 61.8% (n = 102) of participants and for 82.9% (n = 136) they did not differ from local community-acquired pneumonia guidelines. Clinical presentation was recognized as the most important reason for the start of antibiotics (mean score = 4.07 and SD = 1.095 on grading scale from 1 to 5). When antibiotics were started, most respondents rated as the highest the need for coverage of atypical pathogens (mean score = 2.8 and SD = 0.99), followed by Staphylococcus aureus (mean score = 2.67 and SD = 1.05 on bi-modal scale, with values 1 and 2 for disagreement and values 3 and 4 for agreement). In the patients on the ward, 29.1% of respondents chose not to prescribe any antibiotic. Combination of β-lactams and macrolides or fluoroquinolones was reported by 52.4% (n = 87) of respondents. In patients in the ICU, piperacillin/tazobactam was the most commonly prescribed antibiotic. The mean reported duration of antibiotic treatment was 7.12 (SD = 2.44) days.
CONCLUSIONS
The study revealed widespread broad-spectrum antibiotic use in patients with COVID-19. Implementation of antimicrobial stewardship principles is warranted to mitigate the negative consequences of antibiotic therapy.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Intensive Care, Emergency Medicine and Anaesthesiology (DINA) > Clinic and Policlinic for Anaesthesiology and Pain Therapy |
UniBE Contributor: |
Berger-Estilita, Joana Marta |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0305-7453 |
Publisher: |
Oxford University Press |
Language: |
English |
Submitter: |
Jeannie Wurz |
Date Deposited: |
11 Aug 2020 13:27 |
Last Modified: |
09 Aug 2023 00:25 |
Publisher DOI: |
10.1093/jac/dkaa326 |
PubMed ID: |
32766706 |
BORIS DOI: |
10.7892/boris.145740 |
URI: |
https://boris.unibe.ch/id/eprint/145740 |
Actions (login required)
 |
Edit item |